Skip to main content

Table 2 Univariate and multivariable analysis for biochemical recurrence-free survival in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Variables

Univariate

Multivariable

HR

95%CI

P value

HR

95%CI

P value

Age

0.92

0.85–1.00

0.035

   

Completion of NAC (medify vs complete)

0.84

0.35–2.02

0.689

   

Baseline PSA level (continuous)

1.02

1.01–1.04

0.006

1.03

1.01–1.05

0.010

Gleason score at diagnosis (≥8 vs ≤7)

2.00

0.74–5.38

0.169

   

Extended lymph node dissection (yes vs no)

1.51

0.60–3.81

0.382

   

pT (≥3 vs ≤2)

4.40

1.91–10.13

< 0.001

1.13

0.30–4.22

0.854

pN (+ or 0)

4.60

1.90–11.11

0.001

3.94

1.06–14.62

0.040

Resective margin (positive or negative)

2.00

0.46–8.67

0.355

   

Nuclear expression of AR in epitherial cell (High vs low)

3.00

1.22–7.35

0.017

0.98

0.32–3.02

0.971

Nuclear expression of GR in epitherial cell (High vs low)

1.82

0.79–4.18

0.161

   

Nuclear expression of ERα in stromal cell (High vs low)

2.37

0.84–6.64

0.101

   

Nuclear expression of PR in stromal cell (High vs low)

0.45

0.20–1.02

0.054

   

Nuclear expression of YAP in epitherial cell (High vs low)

2.44

1.08–5.55

0.033

3.32

1.32–8.37

0.011

Cytoplasmic expression of MOB4A in epitherial cell (High vs low)

1.73

0.77–3.91

0.190

   
  1. NAC neoadjuvant treatment, PSA prostate specific antigen, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor